multisystem inflammatory syndrome in children
GPTKB entity
Statements (44)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:disease
|
| gptkbp:abbreviation |
MIS-C
|
| gptkbp:affects |
children
|
| gptkbp:age |
children under 21 years
|
| gptkbp:alsoKnownAs |
pediatric multisystem inflammatory syndrome
|
| gptkbp:associatedWith |
gptkb:COVID-19
|
| gptkbp:cause |
gptkb:SARS-CoV-2_infection
post-infectious immune response |
| gptkbp:complication |
multi-organ failure
cardiac involvement coronary artery aneurysm |
| gptkbp:diagnosedBy |
laboratory tests
imaging clinical criteria |
| gptkbp:firstDescribed |
2020
|
| gptkbp:guidanceSystem |
gptkb:CDC_guidelines
gptkb:WHO_guidelines Royal College of Paediatrics and Child Health guidelines |
| https://www.w3.org/2000/01/rdf-schema#label |
multisystem inflammatory syndrome in children
|
| gptkbp:ICD-10_code |
U10.9
|
| gptkbp:mortalityRate |
low
|
| gptkbp:notableOutbreaks |
Europe 2020
United States 2020 |
| gptkbp:onset |
2-6 weeks after COVID-19 infection
|
| gptkbp:prevalence |
rare
|
| gptkbp:relatedTo |
gptkb:toxic_shock_syndrome
gptkb:Kawasaki_disease |
| gptkbp:symptom |
fever
shock vomiting diarrhea abdominal pain conjunctivitis rash lymphadenopathy hypotension mucocutaneous inflammation myocardial dysfunction |
| gptkbp:treatment |
supportive care
corticosteroids anticoagulation immunoglobulin therapy |
| gptkbp:bfsParent |
gptkb:Kawasaki_Disease
|
| gptkbp:bfsLayer |
6
|